CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Oncology

What’s the alternative to Xenograft models in Oncology?


There is a growing need for novel therapeutic treatments against cancer to help tackle the rising prevalence. Unfortunately, oncology drug attrition rates during clinical development remain high. Having human-relevant PK and PD information available earlier in drug development could help reduce attrition.

Accurately predicting the response of tumors to human pharmacokinetic (PK) profiles in vitro is challenging and modeling human tissue-specific biology in xenograft animal models can give rise to poor clinical translatability. Poor correlation between preclinical PK and pharmacodynamics (PD) parameters and clinical studies is one reason for the high drug failure rates.

Our solution

The in vitro assay behind our Oncology Contract Research Services uses a proprietary microphysiological system (MPS), the PhysioMimix™ PK, that administers time-varying drug concentrations to human 3D tumor models, exposing them to a PK profile rather than static concentration. Drug combinations, personalized medicine, dose schedules, and PK/PD relationships can be tested in this manner to explore a greater experimental space than possible using xenograft models.

Until now the effects of PK could only be studied in silico or in vivo. The PhysioMimix PK oncology assay enables the relationship between PK, PD, and efficacy to be studied at scale in the lab, for any 2D or 3D cell line, organoid, or patient-derived tumor model.

Understanding and optimizing the PK/PD/efficacy relationship is key to developing new oncology drugs. By addressing a workflow gap, our PK assay provides a unique means to explore these relationships in vitro. This approach lowers the cost and time to define the relationship, supporting improved drug discovery success rates.

Oncology services in the lab

Studying PK/PD relationships in oncology

Limitations of current techniques

  • PK/PD relationship can only be tested preclinically in animal models (xenograft)
  • Non-human PK profiles are often different from human PK profiles, stimulating different responses
  • In silico predictions can only be validated in animals or clinical studies 
  • Optimization of drug combinations and dose schedules requires extensive animal studies
  • Animal models and patient-derived materials for studies are large and costly

Advancements with PhysioMimix OOC

  • Test predicted PK/PD relationships earlier in drug discovery
  • Directly compare animal and human PK to understand translatability to clinical studies
  • Test in silico predictions and build confidence
  • Explore multiple possible combinations or drug dose schedules in vitro ahead of preclinical animal studies
  • Multiple models can be tested within a single well plate, allowing for a cost-effective way to interrogate different conditions

​

​

Uniquely and rapidly discover the most efficacious novel treatments


Recapitulate in vivo or in silico drug PK profiles to create bespoke treatment regimens and monitor different therapeutic responses to determine effects on tumor biology. Multiple drugs can be combined to treat each tumor group/type, dosing e.g. BID (twice daily), QD (once daily), or Q.week (once weekly).

Drug comparison graphs

Recapitulate clinical efficacy in vitro


Detect distinct responses to mono- or combination therapies in 3D tumor models. Following exposure to clinically relevant drug dosing regimens for multiple weeks, tumors are assessed for cell health and specific drug response biomarkers (e.g. DNA damage – green).

cell responses
CN Bio scientist working on oncology services in lab

Access our Oncology Service

Access the power of PhysioMimix PK via our CRO Service to perform experiments that wouldn’t otherwise be possible. Through a collaborative approach, our experts work with you to plan and execute your study.

Bespoke projects are carried out by our dedicated team of scientists in our CRO facility providing you with actionable data within weeks.

Learn more

Featured resources

Scientific publications

PLOS 2022 DS PK Graphic |

A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

Webinars

web s3e4 |

Bringing Life to PK Profiles: In Vivo-Relevance From an In Vitro Environment.

Posters

In vitro assessment of combination dosing regimens with in vivo like PK EDIT |

In vitro assessment of combination dosing regimen with in vivo-like pharmacokinetic concentration profiles enabled by a microfluidic addition and removal device

View all Oncology related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023